MajesTEC-1: Bispecific Antibody Teclistamab for Relapsed or Refractory Multiple Myeloma

MajesTEC-1: Bispecific Antibody Teclistamab for Relapsed or Refractory Multiple Myeloma

header-info

The bispecific antibody teclistamab produced responses in nearly two-thirds of patients with relapsed or refractory multiple myeloma who had triple-class exposure to an immunomodulatory drug, proteasome inhibitor, and anti-CD38 antibody.